

# Shoshana H Ballew

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6007220/publications.pdf>

Version: 2024-02-01

99  
papers

28,741  
citations

53751

45  
h-index

33869

99  
g-index

101  
all docs

101  
docs citations

101  
times ranked

39728  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	6.3	8,569
2	Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1223-1249.	6.3	3,928
3	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994.	6.3	3,269
4	Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2020, 395, 709-733.	6.3	2,858
5	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1345-1422.	6.3	1,879
6	New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race. <i>New England Journal of Medicine</i> , 2021, 385, 1737-1749.	13.9	1,236
7	Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2518.	3.8	760
8	Cluster-Randomized Trial of a Mobile Phone Personalized Behavioral Intervention for Blood Glucose Control. <i>Diabetes Care</i> , 2011, 34, 1934-1942.	4.3	584
9	Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate. <i>New England Journal of Medicine</i> , 2016, 374, 411-421.	13.9	354
10	Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. <i>American Journal of Kidney Diseases</i> , 2020, 75, 84-104.	2.1	311
11	Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. <i>European Heart Journal</i> , 2018, 39, 1535-1542.	1.0	218
12	Acute Kidney Injury After Major Surgery: A Retrospective Analysis of Veterans Health Administration Data. <i>American Journal of Kidney Diseases</i> , 2016, 67, 872-880.	2.1	216
13	A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. <i>American Journal of Kidney Diseases</i> , 2015, 66, 602-612.	2.1	210
14	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 115-127.	5.5	199
15	Global Cardiovascular and Renal Outcomes of Reduced GFR. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2167-2179.	3.0	194
16	Performance and Limitations of Administrative Data in the Identification of AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 682-689.	2.2	148
17	Cigarette Smoking, Smoking Cessation, and Long-Term Risk of Major Atherosclerotic Diseases. <i>Journal of the American College of Cardiology</i> , 2019, 74, 498-507.	1.2	145
18	Conversion of Urine Protein–Creatinine Ratio or Urine Dipstick Protein to Urine Albumin–Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis. <i>Annals of Internal Medicine</i> , 2020, 173, 426-435.	2.0	144

#	ARTICLE	IF	CITATIONS
19	Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. <i>BMJ: British Medical Journal</i> , 2019, 364, k5301.	2.4	139
20	A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury. <i>American Journal of Kidney Diseases</i> , 2015, 66, 591-601.	2.1	138
21	Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. <i>Kidney International</i> , 2018, 93, 1442-1451.	2.6	124
22	Development of Risk Prediction Equations for Incident Chronic Kidney Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2104.	3.8	124
23	Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	123
24	Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 718-728.	5.5	110
25	Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1746-1755.	3.0	109
26	GFR Decline and Subsequent Risk of Established Kidney Outcomes: A Meta-analysis of 37 Randomized Controlled Trials. <i>American Journal of Kidney Diseases</i> , 2014, 64, 860-866.	2.1	108
27	Subclinical Atherosclerosis Measures for Cardiovascular Prediction in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 439-447.	3.0	106
28	Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. <i>Kidney International</i> , 2017, 91, 244-251.	2.6	104
29	Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System. <i>Hypertension</i> , 2016, 67, 1181-1188.	1.3	99
30	Frailty, Kidney Function, and Polypharmacy: The Atherosclerosis Risk in Communities (ARIC) Study. <i>American Journal of Kidney Diseases</i> , 2017, 69, 228-236.	2.1	92
31	Past Decline Versus Current eGFR and Subsequent ESRD Risk. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2447-2455.	3.0	78
32	CKD and Cardiovascular Disease in the Atherosclerosis Risk in Communities (ARIC) Study: Interactions With Age, Sex, and Race. <i>American Journal of Kidney Diseases</i> , 2013, 62, 691-702.	2.1	76
33	Glucose Peaks and the Risk of Dementia and 20-Year Cognitive Decline. <i>Diabetes Care</i> , 2017, 40, 879-886.	4.3	75
34	Cohort Profile: The Chronic Kidney Disease Prognosis Consortium. <i>International Journal of Epidemiology</i> , 2013, 42, 1660-1668.	0.9	69
35	Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2018, 93, 1281-1292.	2.6	69
36	Socioeconomic Status and Incidence of Hospitalization With Lower Extremity Peripheral Artery Disease: Atherosclerosis Risk in Communities Study. <i>Journal of the American Heart Association</i> , 2017, 6,	1.6	66

#	ARTICLE	IF	CITATIONS
37	Cardiac and Kidney Markers for Cardiovascular Prediction in Individuals With Chronic Kidney Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1770-1777.	1.1	57
38	Identification of Incident CKD Stage 3 in Research Studies. <i>American Journal of Kidney Diseases</i> , 2014, 64, 214-221.	2.1	56
39	Kidney Function and Fracture Risk: The Atherosclerosis Risk in Communities (ARIC) Study. <i>American Journal of Kidney Diseases</i> , 2016, 67, 218-226.	2.1	54
40	Kidney Function, Polypharmacy, and Potentially Inappropriate Medication Use in a Community-Based Cohort of Older Adults. <i>Drugs and Aging</i> , 2018, 35, 735-750.	1.3	54
41	Albuminuria Testing in Hypertension and Diabetes: An Individual-Participant Data Meta-Analysis in a Global Consortium. <i>Hypertension</i> , 2021, 78, 1042-1052.	1.3	52
42	Associations Between Kidney Disease Measures and Regional Pulse Wave Velocity in a Large Community-Based Cohort: The Atherosclerosis Risk in Communities (ARIC) Study. <i>American Journal of Kidney Diseases</i> , 2018, 72, 682-690.	2.1	51
43	Incorporating kidney disease measures into cardiovascular risk prediction: Development and validation in 9 million adults from 72 datasets. <i>EClinicalMedicine</i> , 2020, 27, 100552.	3.2	50
44	Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations. <i>Diabetes Care</i> , 2021, 44, 2000-2009.	4.3	50
45	Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. <i>American Journal of Kidney Diseases</i> , 2019, 73, 206-217.	2.1	49
46	Lifetime Risk of Lower-Extremity Peripheral Artery Disease Defined by Ankle-Brachial Index in the United States. <i>Journal of the American Heart Association</i> , 2019, 8, e012177.	1.6	48
47	Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate. <i>Kidney International</i> , 2016, 90, 1109-1114.	2.6	47
48	Candidate Surrogate End Points for ESRD after AKI. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2851-2859.	3.0	47
49	High-sensitivity cardiac troponin and natriuretic peptide with risk of lower-extremity peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) Study. <i>European Heart Journal</i> , 2018, 39, 2412-2419.	1.0	46
50	Serum Potassium, Mortality, and Kidney Outcomes in the Atherosclerosis Risk in Communities Study. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1403-1412.	1.4	45
51	Kidney Failure and ESRD in the Atherosclerosis Risk in Communities (ARIC) Study: Comparing Ascertainment of Treated and Untreated Kidney Failure in a Cohort Study. <i>American Journal of Kidney Diseases</i> , 2015, 66, 231-239.	2.1	42
52	American Heart Association's Life's Simple 7 at Middle Age and Prognosis After Myocardial Infarction in Later Life. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	42
53	Short-Term Prognostic Impact of Arterial Stiffness in Older Adults Without Prevalent Cardiovascular Disease. <i>Hypertension</i> , 2019, 74, 1373-1382.	1.3	40
54	Ankle-brachial index and physical function in older individuals: The Atherosclerosis Risk in Communities (ARIC) study. <i>Atherosclerosis</i> , 2017, 257, 208-215.	0.4	37

#	ARTICLE	IF	CITATIONS
55	Cardiovascular Risk Prediction in CKD. <i>Seminars in Nephrology</i> , 2018, 38, 208-216.	0.6	35
56	Cardiovascular risk prediction in people with chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 25, 518-523.	1.0	33
57	Kidney Disease Measures and Left Ventricular Structure and Function: The Atherosclerosis Risk in Communities Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	32
58	Chronic kidney disease measures and the risk of abdominal aortic aneurysm. <i>Atherosclerosis</i> , 2018, 279, 107-113.	0.4	32
59	Association of Kidney Disease Measures with Cause-Specific Mortality: The Korean Heart Study. <i>PLoS ONE</i> , 2016, 11, e0153429.	1.1	31
60	Kidney Function, Proteinuria, and Cancer Incidence: The Korean Heart Study. <i>American Journal of Kidney Diseases</i> , 2017, 70, 512-521.	2.1	31
61	Repeat falls and the recovery of social participation in the year post-hip fracture. <i>Age and Ageing</i> , 2009, 38, 570-575.	0.7	29
62	Association of Kidney Function and Albuminuria With Prevalent and Incident Hypertension: The Atherosclerosis Risk in Communities (ARIC) Study. <i>American Journal of Kidney Diseases</i> , 2015, 65, 58-66.	2.1	28
63	Race, Serum Potassium, and Associations With ESRD and Mortality. <i>American Journal of Kidney Diseases</i> , 2017, 70, 244-251.	2.1	28
64	The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1847-1858.	3.0	28
65	Fibrosis and Inflammatory Markers and Long-Term Risk of Peripheral Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2322-2331.	1.1	27
66	APOL1 Kidney Risk Variants and Cardiovascular Disease: An Individual Participant Data Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2027-2036.	3.0	26
67	Albuminuria, Kidney Function, and Cancer Risk in the Community. <i>American Journal of Epidemiology</i> , 2020, 189, 942-950.	1.6	26
68	Association Between Midlife Physical Activity and Incident Kidney Disease: The Atherosclerosis Risk in Communities (ARIC) Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 74-81.	2.1	26
69	Albuminuria as a Predictor of Cardiovascular Outcomes in Patients With Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2019, 8, e010546.	1.6	25
70	2017 ACC/AHA blood pressure classification and incident peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) Study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 51-59.	0.8	25
71	The Role of Spiritual Experiences and Activities in the Relationship Between Chronic Illness and Psychological Well-Being. <i>Journal of Religion and Health</i> , 2012, 51, 1386-1396.	0.8	23
72	Influence of Chronic Kidney Disease on Cardiac Structure and Function. <i>Current Hypertension Reports</i> , 2015, 17, 581.	1.5	23

#	ARTICLE	IF	CITATIONS
73	Prevalence of Opioid, Gabapentinoid, and NSAID Use in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1886-1888.	2.2	21
74	Retinal microvascular findings and risk of incident peripheral artery disease: An analysis from the Atherosclerosis Risk in Communities (ARIC) Study. <i>Atherosclerosis</i> , 2020, 294, 62-71.	0.4	21
75	Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study. <i>Atherosclerosis</i> , 2018, 274, 86-93.	0.4	20
76	Conventional and Novel Lipid Measures and Risk of Peripheral Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1229-1238.	1.1	19
77	International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-AMI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	17
78	Chronic kidney disease measures for cardiovascular risk prediction. <i>Atherosclerosis</i> , 2021, 335, 110-118.	0.4	17
79	Kidney Measures with Diabetes and Hypertension on Cardiovascular Disease: The Atherosclerosis Risk in Communities Study. <i>American Journal of Nephrology</i> , 2015, 41, 409-417.	1.4	16
80	Socioeconomic status and risk of kidney dysfunction: the Atherosclerosis Risk in Communities study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1361-1368.	0.4	16
81	Serum albumin and risks of hospitalization and death: Findings from the Atherosclerosis Risk in Communities study. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 2865-2876.	1.3	15
82	Carotid Intima-Media Thickness and Incident ESRD: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1197-1205.	2.2	14
83	Hospitalization Risk among Older Adults with Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2019, 50, 212-220.	1.4	13
84	Endothelial dysfunction and the risk of heart failure in a community-based study: the Multi-Ethnic Study of Atherosclerosis. <i>ESC Heart Failure</i> , 2020, 7, 4231-4240.	1.4	13
85	Risk of peripheral artery disease according to race and sex: The Atherosclerosis Risk in Communities (ARIC) study. <i>Atherosclerosis</i> , 2021, 324, 52-57.	0.4	12
86	Prognostic Value of Chronic Kidney Disease Measures in Patients With Cardiac Disease. <i>Circulation Journal</i> , 2017, 81, 1075-1084.	0.7	11
87	Physical Activity and Subsequent Risk of Hospitalization With Peripheral Artery Disease and Critical Limb Ischemia in the ARIC Study. <i>Journal of the American Heart Association</i> , 2019, 8, e013534.	1.6	11
88	Ankle-brachial index and subsequent risk of incident and recurrent cardiovascular events in older adults: The Atherosclerosis Risk in Communities (ARIC) study. <i>Atherosclerosis</i> , 2021, 336, 39-47.	0.4	11
89	Novel "Predictor Patch" Method for Adding Predictors Using Estimates From Outside Datasets: A Proof-of-Concept Study Adding Kidney Measures to Cardiovascular Mortality Prediction. <i>Circulation Journal</i> , 2019, 83, 1876-1882.	0.7	10
90	Kidney function, bone-mineral metabolism markers, and future risk of peripheral artery disease. <i>Atherosclerosis</i> , 2017, 267, 167-174.	0.4	9

#	ARTICLE	IF	CITATIONS
91	Dyskalemia, its patterns, and prognosis among patients with incident heart failure: A nationwide study of US veterans. PLoS ONE, 2019, 14, e0219899.	1.1	9
92	Diabetes, its duration, and the long-term risk of abdominal aortic aneurysm: The Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis, 2020, 313, 137-143.	0.4	9
93	Race, <sc>APOL1</sc> Risk Variants, and Clinical Outcomes among Older Adults: The <sc>ARIC</sc> Study. Journal of the American Geriatrics Society, 2021, 69, 155-163.	1.3	9
94	Estimating Kidney Failure Risk Using Electronic Medical Records. Kidney360, 2021, 2, 415-424.	0.9	9
95	Retinopathy and Risk of Kidney Disease in Persons With Diabetes. Kidney Medicine, 2021, 3, 808-815.e1.	1.0	9
96	Albuminuria and Prognosis Among Individuals With Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology, 2021, 78, 87-89.	1.2	8
97	Ankle-Brachial Index and Subsequent Risk of Severe Ischemic Leg Outcomes: The ARIC Study. Journal of the American Heart Association, 2021, 10, e021801.	1.6	5
98	Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction. American Heart Journal, 2019, 216, 62-73.	1.2	4
99	A Practical Guide to Interpret Individual Participant Data Meta-analysis of Observational Studies. American Journal of Kidney Diseases, 2021, 78, 464-467.	2.1	0